摘要
目的:系统评估LncRNA表达与卵巢癌患者临床病理特征的关系及其在卵巢癌患者中的预后价值。方法:计算机检索Pub Med、EMBASE、Cochrane Library、中国生物医学文献数据库(CBM)、中国知网(CNKI)和万方数据库,检索时间为建库至2016年7月22日,纳入评估LncRNA表达水平与卵巢癌预后的研究,2名研究员进行文献筛选、数据提取和质量评价后,采用STATA 12.0进行统计分析。结果:共纳入13篇研究。Meta分析结果提示,卵巢癌中LncRNA表达水平与FIGO分期相关(P=0.000),与其余病理特征无关。与LncRNA低表达组比较,LncRNA高表达组患者的OS较短(HR=1.97,95%CI为1.69,2.31,P=0.000)。结论:LncRNA高表达提示卵巢癌患者的OS较短,是卵巢癌预后的一个危险因素。
Objective:To systematically assess whether the LncRNA expression was as-sociated with overall survival and clinical feature for ovarian cancer patients. Methods:The da-tabases including PubMed,EMBASE database,the Cochrane Library,CNKI,CBM,and Wanfang database were searched from inception to July 22,2016 to identify the eligible studies. Literature selection,data extraction,and quality assessment were performed by two independent reviewers. STATA 12. 0 software was used for meta-analysis. Results:A total of 13 studies were included. The results of meta-analysis showed that the FIGO stage was associated with LncRNA expression ( P=0 . 000 ) . There were no statistical significant differences between other clinical features and LncRNA. Compared with LncRNA low expression,LncRNA high expression was associated with poor OS (HR=1. 97,95%CI为1. 69~2. 31,P=0. 000). Conclusions:LncRNA high expres-sion was associated with poor OS,which could be a predictor of short-term survival.
作者
潘青
郭丹凤
同芙菊
李悦
王晓慧
Pan Qing Guo Danfeng Tong Fuju et al(Department of Obstetrics and Gynaecology, First Hospital of Lanzhou University,Lanzhou 73000)
出处
《现代妇产科进展》
CSCD
北大核心
2016年第12期900-903,共4页
Progress in Obstetrics and Gynecology